Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (270)	11/11/2003 8:49:43 PM
From: muddphudd	Read Replies (1) \| Respond to of 371

Bad news for the stock price today: Biotech stocks stumble Immunomedics, Vertex plunge after setbacks By Ted Griffith, CBS.MarketWatch.com Last Update: 4:18 PM ET Nov. 11, 2003 BOSTON (CBS.MW) -- Biotechnology stocks headed lower Tuesday, with shares of Immunomedics and Vertex Pharmaceuticals leading the retreat after separate setbacks for key experimental drugs. The Amex Biotechnology Index (BTK: news, chart, profile) slumped 3.1 percent to 437.29, and the Nasdaq Biotechnology Index (NBI: news, chart, profile) dropped 1.6 percent to 673.39. Shares of Immunomedics (IMMU: news, chart, profile) plunged $3.87, or 53.4 percent, to $3.38. The small biotech firm disclosed that partner Amgen (AMGN: news, chart, profile) doesn't plan to move ahead with a crucial clinical trial of Immunomedics' experimental cancer therapy, called epratuzumab. Amgen, the world's largest biotechnology firm, is also in discussions that could lead to the return of rights to epratuzumab to Immunomedics. Amgen shares edged down 16 cents to $58.98. I still believe that epratuzumab is safe and effective. Is this a good time to pick up some IMMU? comments, suggestions anyone?